Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: tracy s. J Clin Invest. 2006 Oct;116(10):2695-706. doi: 10.1172/JCI28656. Epub 2006 Aug 10. J Clin Invest. 2006. PMID: 16906227 Free PMC article.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: tracy s. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: tracy si. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
Patients with TP53-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.
Sumransub N, Steinwand GK, Cordner K, Lee Y, Cao Q, Allred J, Bachanova V, Juckett M, Eckfeldt C, Maakaron JE, Tracy SI, Ramesh V, Nelson AC, Yohe S, Sachs Z. Sumransub N, et al. Among authors: tracy si. Cancers (Basel). 2024 Aug 7;16(16):2784. doi: 10.3390/cancers16162784. Cancers (Basel). 2024. PMID: 39199557 Free PMC article.
Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Aldoss I, et al. Among authors: tracy si. Blood Adv. 2024 Aug 2:bloodadvances.2024013747. doi: 10.1182/bloodadvances.2024013747. Online ahead of print. Blood Adv. 2024. PMID: 39093952
371 results